Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

NCT06714526 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Intracranial Atherosclerosis

Interventions

GENETIC: Point-of-Care CYP2C19 Testing
DRUG: ticagrelor + aspirin
DRUG: clopidogrel + aspirin

Sponsor

Sunnybrook Health Sciences Centre